Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Journal of the Neurological Sciences|September 7, 2015
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosisLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
Brain and Behavior|March 7, 2024
Medically unexplained symptoms are common in women in tertiary neurological healthcare center: A survey cohort study of persons investigated for suspected multiple sclerosisLenka Novakova, Anna Karin Hedström, Markus Axelsson, et al.
Frontiers in Immunology|March 25, 2017
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple SclerosisAvadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, et al.
Frontiers in Neurology|April 3, 2023
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective surveySofia Sandgren, Lenka Novakova, Markus Axelsson, et al.
Plos One|April 4, 2018
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkersLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
Journal of Medical Economics|May 10, 2021
Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in SwedenCarlos Acosta, Mattia Gianinazzi, Thibaut Dort, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2016
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantroneAnnika Öhrfelt, Markus Axelsson, Clas Malmeström, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 29, 2014
Age-dependent effects on the treatment response of natalizumab in MS patientsHenrik Matell, Jan Lycke, Anders Svenningsson, et al.
Multiple Sclerosis and Related Disorders|September 18, 2024
The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center studySofia Sandgren, Lenka Novakova, Anna Nordin, et al.
European Journal of Neurology|April 17, 2026
Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple SclerosisIgal Rosenstein, Markus Axelsson, Magnus Johnsson, et al.
Pageof 12